Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Stroke

Finding atrial fibrillation after cryptogenic stroke

Nearly 40% of ischaemic strokes remain cryptogenic when no clear aetiology is identified after a thorough initial investigation. Two recent articles in Stroke described extended arrhythmia monitoring modalities to reveal paroxysmal atrial fibrillation in patients with ischaemic stroke, with implications for decisions regarding anticoagulation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Liao, J., Khalid, Z., Scallan, C., Morillo, C. & O'Donnell, M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38, 2935–2940 (2007).

    Article  PubMed  Google Scholar 

  2. Hart, R. G. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 35, 183–187 (2000).

    Article  CAS  PubMed  Google Scholar 

  3. Marini, C. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36, 1115–1119 (2005).

    Article  PubMed  Google Scholar 

  4. Barthélémy, J. C. et al. Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann. Noninvasive Electrocardiol. 8, 194–199 (2003).

    Article  PubMed  Google Scholar 

  5. Jabaudon, D., Sztajzel, J., Sievert, K., Landis, T. & Sztajzel, R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 35, 1647–1651 (2004).

    Article  PubMed  Google Scholar 

  6. Flint, A. C. et al. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) registry. Stroke 43, 2788–2790 (2012).

    Article  PubMed  Google Scholar 

  7. Rizos, T. et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke 43, 2689–2694 (2012).

    Article  PubMed  Google Scholar 

  8. Ip, J. et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with ICD and CRT-D devices: rationale, design and clinical characteristics of the initially enrolled cohort: the IMPACT Study. Am. Heart J. 158, 364–370e1 (2009).

    Article  PubMed  Google Scholar 

  9. de Vos, C. B. et al. Progression from paroxysmal to persistent atrial fibrillation: clinical correlates and prognosis. J. Am. Coll. Cardiol. 55, 725–731 (2010).

    Article  PubMed  Google Scholar 

  10. Sinha, A. M. et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am. Heart J. 160, 36–41 (2010).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jonathan L. Halperin.

Ethics declarations

Competing interests

J. L. Halperin has received consulting fees from Bayer AG HealthCare, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Janssen Pharmaceuticals, Pfizer and Sanofi-Aventis for advisory activities involving the development of new anticoagulant drugs. He receives consulting fees from Biotronik, Inc. as Co-Chairman of the Steering Committee for the IMPACT clinical trial and from Medtronic as a member of the Steering Committee of the REVEAL-AF study. He served on the Operations Committee for the PALLAS clinical trial, sponsored by Sanofi-Aventis. He serves on the Executive Steering Committee of the GLORIA-AF Registry, sponsored by Boehringer Ingeheim, and as Chairman of the Data and Safety Monitoring Committee for a clinical trial comparing ticagrelor and clopidogrel for prevention of major adverse cardiovascular events in patients with peripheral arterial disease, sponsored by AstraZeneca. D. Pain declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pain, D., Halperin, J. Finding atrial fibrillation after cryptogenic stroke. Nat Rev Neurol 8, 666–667 (2012). https://doi.org/10.1038/nrneurol.2012.228

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.228

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing